Table_6_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”

Table_2_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”

Table_7_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”

Table_1_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”

Table_5_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”

RNLS distribution in human precursor and PDAC tissue. by Yasheen Gao (6090842)

Table_1_RiCRN1, a Crinkler Effector From the Arbuscular Mycorrhizal Fungus Rhizophagus irregularis, Functions in Arbuscule Development.xlsx by Stefanie Voß (5712605)

“…Here, we have identified an AM fungal effector that participates in this developmental step of the symbiosis. RiCRN1 is a crinkler (CRN) effector that belongs to a subfamily of secreted CRN proteins from R. irregularis. …”

Table_2_RiCRN1, a Crinkler Effector From the Arbuscular Mycorrhizal Fungus Rhizophagus irregularis, Functions in Arbuscule Development.XLSX by Stefanie Voß (5712605)

“…Here, we have identified an AM fungal effector that participates in this developmental step of the symbiosis. RiCRN1 is a crinkler (CRN) effector that belongs to a subfamily of secreted CRN proteins from R. irregularis. …”

Table_3_RiCRN1, a Crinkler Effector From the Arbuscular Mycorrhizal Fungus Rhizophagus irregularis, Functions in Arbuscule Development.XLSX by Stefanie Voß (5712605)

“…Here, we have identified an AM fungal effector that participates in this developmental step of the symbiosis. RiCRN1 is a crinkler (CRN) effector that belongs to a subfamily of secreted CRN proteins from R. irregularis. …”

Table_3_Living at the Edge: Increasing Stress for Plants 2–13 Years After the Retreat of a Tropical Glacier.DOCX by Fabien Anthelme (475650)

“…<p>Rapid warming is a major threat for the alpine biodiversity but, at the same time, accelerated glacial retreat constitutes an opportunity for taxa and communities to escape range contraction or extinction. …”

Table_1_Living at the Edge: Increasing Stress for Plants 2–13 Years After the Retreat of a Tropical Glacier.DOCX by Fabien Anthelme (475650)

“…<p>Rapid warming is a major threat for the alpine biodiversity but, at the same time, accelerated glacial retreat constitutes an opportunity for taxa and communities to escape range contraction or extinction. …”

Table_4_Living at the Edge: Increasing Stress for Plants 2–13 Years After the Retreat of a Tropical Glacier.DOCX by Fabien Anthelme (475650)

“…<p>Rapid warming is a major threat for the alpine biodiversity but, at the same time, accelerated glacial retreat constitutes an opportunity for taxa and communities to escape range contraction or extinction. …”

Table_2_Living at the Edge: Increasing Stress for Plants 2–13 Years After the Retreat of a Tropical Glacier.DOCX by Fabien Anthelme (475650)

“…<p>Rapid warming is a major threat for the alpine biodiversity but, at the same time, accelerated glacial retreat constitutes an opportunity for taxa and communities to escape range contraction or extinction. …”

Table_5_Living at the Edge: Increasing Stress for Plants 2–13 Years After the Retreat of a Tropical Glacier.DOCX by Fabien Anthelme (475650)

“…<p>Rapid warming is a major threat for the alpine biodiversity but, at the same time, accelerated glacial retreat constitutes an opportunity for taxa and communities to escape range contraction or extinction. …”

Table_1_Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study.docx by Eun-Gyeong Lee (627417)

“…The OS rate in SPBC decreased significantly with advanced stage and older age.…”

Structure of the IHE model. by Dunming Xiao (20531096)

“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”

Results of base case. by Dunming Xiao (20531096)

“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”

Clinical efficacy data. by Dunming Xiao (20531096)

“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”

Cost-effectiveness acceptable curve. by Dunming Xiao (20531096)

“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”

Probabilistic analysis scatterplot. by Dunming Xiao (20531096)

“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”